# Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration

> **NCT01344993** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astellas Institute for Regenerative Medicine** · enrollment: 13 (actual)

## Conditions studied

- Dry Age Related Macular Degeneration

## Interventions

- **BIOLOGICAL:** MA09-hRPE

## Key facts

- **NCT ID:** NCT01344993
- **Lead sponsor:** Astellas Institute for Regenerative Medicine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-09
- **Primary completion:** 2015-08-19
- **Final completion:** 2015-08-19
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01344993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01344993, "Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01344993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*